Researchers investigated whether investigate whether the mononuclear cell fraction of human cord blood , which contains stem cells could be useful in hepatic regenerative medicine. Both histological and biochemical findings of the research were, suggested that improve the health of sick animals, but instead took to a hepatorenal syndrome stem cell transplantation does not.
Today about 17 percent of the world population is affected by liver disease. There is no specific treatment for liver fibrosis in chronic liver disease in chronic liver disease patients receive treatment for orders and its associated complications. In addition, the current therapy for end-stage liver disease, whole liver transplantation, shortage of organ donors shortage of organ donors. Accordingly, novel therapies, requires the use of cord blood stem cells to alleviate the suffering of many patients. This work, however, emphasizes the need for further research in the area of hepatic regenerative medicine. Consejer a Health Dept. And Federaci? n de Cajas de Ahorro de Castilla y Le? in in the November issue the journal Cell transplantation..Fighting This field the which to address the problems of the patients with reduced and reduce the cardiovascular function have - a population untreatable the largest individual order patient segments in the health care represents. New medications and innovative devices patients quality-of -life have improved, however have done little to decrease the mortality and morbidity. Transplantation remain a high-risk procedure by chronic care and histocompatibility any questions. Synthetic materials, such as tissue substitute suffer biocompatibility of problem and are sensitive to thrombosis.